BioCatalystWatch
BDTXWorkspace / BDTX / OverviewCompany library
Black Diamond Therapeutics, Inc. logo

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. (BDTX)

Website

Price
Market cap
Next catalystPotential Phase 3 initiation in Q2 2027, following sufficient Cohort 4 safety-data submission and subject to financingSilevertinib — planned global Phase 3 in frontline EGFR-NCM NSCLC · Trial initiationCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

Silevertinib (BDTX-1535)Silevertinib — planned global Phase 3 in frontline EGFR-NCM NSCLC

EGFR

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Silevertinib (BDTX-1535)Silevertinib — planned global Phase 3 in frontline EGFR-NCM NSCLC

EGFR

PreINDP1P2FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Other pipelines

BDTX-FGFR

PreINDP1P2P3FilingApproved

Partner / License out

RAF × BRAF

PreINDP1P2P3FilingApproved

FGFR2 × FGFR3

PreINDP1P2P3FilingApproved

History / paused

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Company funding outlook

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

BDTX PR & News

PR & News

BDTX SEC archive